Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 7/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300240 | 0.84 | OPRK1 (0.32) | — | |
| SCHEMBL6295807 | 0.82 | TSHR (0.34) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL5870104 | 0.78 | HPGD (0.38) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL6700232 | 0.75 | METAP2 (0.35) | CTSSMETAP2METAP1 | |
| SCHEMBL5870316 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL5870320 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL4448207 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL5870360 | 0.74 | ALDH1A1 (0.40) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL6294783 | 0.72 | CTSS (0.39) | CTSSMETAP2METAP1 | |
| SCHEMBL6295607 | 0.71 | OPRK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1358176-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | ALDH1A1 2942/4885HPGD 2957/4885SMN1; SMN2 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.